Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the potential of carbon monoxide (CO) to decrease
elevated blood pressure in the pulmonary artery. This symptom is seen in patients with
pulmonary arterial hypertension, a rare disease that causes fatigue, dizziness, and shortness
of breath because the blood vessels that supply the lungs narrow, forcing the heart to work
harder to push blood through. Previous studies in the laboratory have shown that carbon
monoxide has promise in treating these symptoms.
Subjects in this study are being asked to undergo a new type of treatment to improve
pulmonary arterial hypertension by breathing CO gas. CO is a colorless, tasteless, odorless
gas usually found in car exhaust or cigarette smoke. It is administered with a continuous
flow of air. Subjects will undergo a screening process during which it will be determined if
they are eligible for the study. After the screening process, if subjects meet eligibility
criteria for the study, they will begin carbon monoxide treatment through a cushioned mask
that is placed over the nose and mouth. This treatment will last for sixteen weeks.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Illinois at Chicago
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)